Literature DB >> 2521525

Diphosphonates inhibit human osteoblast secretion and proliferation.

M A Khokher1, P Dandona.   

Abstract

In view of the beneficial effect of diphosphonates in Paget's disease and their suppressive effect on alkaline phosphatase, the action of three diphosphonates (aminohydroxypropylidene diphosphonate [APD], clodronate, and didronel) on cultured human osteoblasts in vitro was investigated. All three inhibited basal and 1,25(OH)2 cholecalciferol-stimulated alkaline phosphatase secretion and [3H]thymidine uptake by osteoblasts. It is concluded that diphosphonates consistently inhibit human osteoblasts through a direct action in addition to their known effect on inhibiting bone resorption and that these actions together may form the basis of their beneficial effect in vivo in patients with Paget's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521525     DOI: 10.1016/0026-0495(89)90260-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  12 in total

Review 1.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

2.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

3.  Changes in bone mineral density in patients with Paget's disease treated with risedronate.

Authors:  S Patel; D Pearson; A Bhallah; W Maslanka; D A White; D J Hosking
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

4.  Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.

Authors:  Addolorata Corrado; Francesco Paolo Cantatore; Maria Grano; Silvia Colucci
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

Authors:  Michaël Chaplet; Cédric Detry; Christophe Deroanne; Larry W Fisher; Vincent Castronovo; Akeila Bellahcéne
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

7.  Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis.

Authors:  L Quarta; A Corrado; N Melillo; A Trotta; G Scotto; F d'Onofrio; N Santoro; F P Cantatore
Journal:  Rheumatol Int       Date:  2007-09-26       Impact factor: 2.631

8.  The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts.

Authors:  A Ganguli; C Henderson; M H Grant; S T Meikle; A W Lloyd; I Goldie
Journal:  J Mater Sci Mater Med       Date:  2002-10       Impact factor: 3.896

Review 9.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

10.  When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer.

Authors:  Carmelo Caldarella; Giorgio Treglia; Alessandro Giordano; Luca Giovanella
Journal:  Cancer Manag Res       Date:  2013-06-25       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.